Merck & Co.'s (MRK.US) new drug for pulmonary arterial hypertension has been submitted for approval in China.
AInvestWednesday, Oct 16, 2024 11:20 pm ET
1min read
MRK --

On October 17, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE)'s website showed that Merck (MRK.US) had received a notice of acceptance for its application for the marketing authorization of subcutaneous sotatercept. According to public information, it is a "first-in-class" new biological agent that inhibits the activin signal. The product was approved for marketing in the United States by the FDA in March this year and is used to treat pulmonary arterial hypertension (PAH). This therapy was previously rated by industry media Evaluate as one of the potential blockbuster therapies in 2024.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.